维普期刊资源整合服务平台（V6.5）

85篇 您的检索式：作者名="FLEMING GF"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	A phase I study of weekly temsirollmus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies 显示文摘	Temkin SM Yamada SD Fleming GF	2010	Gynecologic Oncology2010，117，3：	1
2	Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues显示文摘	Melhem A Yamada SD Fleming GF	2009	Clin Cancer Res2009，15，9：	1
3	Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma:a Gynecologic Oncology Group Study显示文摘	Fleming GF Brunetto VL Cella D	2004	J Clin Oncol2004，22，11：	1
4	Bone cells and matrices in orthopedic tissue engineering显示文摘	Fleming JE Jr Comell CN Muschler GF	2000	Orthop Clin North Am2000，31，3：	1
5	Hormone ther- apy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial# 248显示文摘	Fleming GF Filiaci VL Hanjani P	2011	J Clin On- col2011，29，：	1
6	PhaseⅠtrial of ISIS 5132,an antisense oligonucleotide inhibitor of C-raf-1,administered by 24-hour weekly infusion to patients with advanced cancer显示文摘	Rudin CM Holmlund J Fleming GF	2001	Clin Cancer Res2001，7，：	1
7	Phase Ⅲ trial of doxoru- bicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study显示文摘	Fleming GF Bmnetto VL Celia D	2004	J Clin Oncol2004，22，11：	1
8	Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotie genes SGK1 and MKP1/DUSP1 in ovarian tissues 显示文摘	Melhem A Yamada SD Fleming GF	2009	Clin Cancer Res2009，15，9：	1
9	A phase I trial of es- calating doses of trastuzumab combined with daily subcutaneous interleukin 2:report of cancer and leukemia group B 9661 显示文摘	Fleming GF Meropol NJ Rosner GL	2002	Clin Cancer Res2002，8，12：	1
10	Phase trial of doxorubicin plus cisplatinwith or without paclita-xel plus filgrastim in advanced endometrial carcinoma:GynecologicOucologyGroup Study显示文摘	Fleming GF Brunetto VL Cella D	2004	Clin Oncol2004，22，11：	1
11	Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endumetrial carcinoma:a Gynecologic Oncology Group study显示文摘	Fleming GF Brunetto VL Celia D	2004	J Clin Oncol2004，22，：	1
12	Bone cells and matrices in orthopedic tissue engineering显示文摘	Fleming JE Jr Comell CN Muschler GF	2000	Orthop Clin North Am2000，31，：	1
13	Progenitor cell mobilization A phase Ⅱ trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer显示文摘	Fleming GF Wagganer S	2001	Bone Marrow Transplant2001，27，7：	1
14	A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (paclimer) in recurrent ovarian cancer:a gynecologic oncology group study显示文摘	Armstrong DK Fleming GF Markman M	2006	Gynecol Oncol2006，103，2：	1
15	Absence of major peripheral neuropathy in a phase Ⅱ trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and pacritaxel显示文摘	Fleming GF Waggoner SE RotmenschJ	2001	Am J Grin Oncol2001，24，1：	1
16	Phase Ⅱ evaluation of thalidomide in patients with metastatic breast cancer 显示文摘	Winer EP Fleming GF	2000	J Clin Oncol2000，18，14：	1
17	Phase Ⅱ trial of trastuzumab in women with advanced or recurrent,HER2-positive endometrial carcinoma:a Gynecologic Oncology Group study显示文摘	Fleming GF Sill MW Darcy KM	2010	Gynecol Oncol2010，116，1：	1
18	Chemotherapy in endometrial canc-er显示文摘	Obel JC Fleming GF	2006	Chin Adv Hematol Oncol2006，4，4：	1
19	A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies 显示文摘	Temkin SM Yamada SD Fleming GF	2010	Gynecologic oncology2010，117，3：	1
20	Invariant P53 immunostining in primary andrecurrent breast cancer显示文摘	Poelman SM Heimann R Fleming GF	2004	Eur J Cancer2004，40，1：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示